Duloxetine Versus Placebo in Chronic Low Back Pain
18 november 2009 uppdaterad av: Eli Lilly and Company
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients With Chronic Low Back Pain
The primary purpose of your participation in this study is to help answer the following research question, and not to provide you treatment for your condition.
Whether duloxetine once daily can help patients with Chronic Low Back Pain.
Patients who do not have their pain reduced by at least 30% by week 7 will be given 120 mg dose for the duration of the study. After the 13 week double blind period, patients randomized to placebo will switch to duloxetine 60 mg or 120 mg in the 41-week extension period.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Studietyp
Interventionell
Inskrivning (Faktisk)
236
Fas
- Fas 3
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Curitiba, Brasilien, 80060240
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
San Paulo, Brasilien, 04027-000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Sao Paulo, Brasilien, 04026-000
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
-
-
-
-
Amiens, Frankrike, 80054
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Marseille, Frankrike, 13008
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Paris, Frankrike, 75014
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Saint Affrique, Frankrike, 12400
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Saint-Etienne, Frankrike, 42055
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
-
-
-
-
Mexico City, Mexiko, 06700
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Monterrey, Mexiko, 64460
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
San Pedro Garza Garcia, Mexiko, 66260
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
-
-
-
-
Amsterdam, Nederländerna, 1105 AZ
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Rotterdam, Nederländerna, 3039 BD
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
-
-
-
-
Ellwangen, Tyskland, 73479
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Graefelfing, Tyskland, 82166
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Hamburg, Tyskland, 22143
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
Wiesbaden, Tyskland, 65191
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your p
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Male/Female outpatients 18 years of age with chronic low back pain
- Females of child bearing potential must test negative on a pregnancy test at visit 1.
Exclusion Criteria:
- Have a serious or unstable diseases of the heart or blood vessels, liver, kidney, lungs, or blood-related illness
- Problems with decreased blood flow to arms and legs (peripheral vascular disease), or other medical conditions
- Psychiatric conditions that, in the opinion of the investigator, would affect your participation or be likely to lead to hospitalization during the course of the study
- Have acute liver injury (such as hepatitis) or severe cirrhosis
- Have had previous exposure to duloxetine
- Have a body mass index (BMI) over 40
- Have a major depressive disorder
- Require daily narcotics
- Have suicidal risk
- Have a presence of any factors/conditions, medical or other, that in the judgment of the investigator may interfere with performance of study outcome measures
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Duloxetine
30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
|
30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
Andra namn:
|
|
Placebo-jämförare: Placebo
every day (QD), by mouth (PO), 13 weeks
|
every day (QD), by mouth (PO), 13 weeks
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline to Week 13 in Brief Pain Inventory (BPI), 24-hour Average Pain Scores
Tidsram: Baseline, Week 13
|
A self-reported scale that measures the severity of pain based on the average pain over the past 24-hours.
The severity scores range from 0 (no pain) to 10 (pain as severe as you can imagine).
|
Baseline, Week 13
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Patient's Global Impression of Improvement (PGI-I)
Tidsram: Week 13
|
A scale that measures the patient's perception of improvement at the time of assessment.
The score ranges from 1 (very much better) to 7 (very much worse).
|
Week 13
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Roland Morris Disability Questionnaire-24 Item (RMDQ-24) Total Score
Tidsram: Baseline, Week 13, Week 54
|
Roland-Morris questionnaire will be completed by the patient and measures the degree of disability due to back pain.
The questionnaire consists of 24 statements and the patient is instructed to put a mark next to each appropriate statement.
The number of statements marked will be added up by the clinician and a total score is given.
The total score ranges from 0 (no disability) to 24 (severe disability).
|
Baseline, Week 13, Week 54
|
|
Change From Baseline to Week 13 Endpoint in Weekly Mean of 24-hour Average Pain, Night Pain and Worst Pain by 11-Point Likert Scale
Tidsram: Baseline, Week 13
|
24-hour average pain severity scores recorded daily on an 11-point Likert scale, an ordinal scale ranging from 0 (no pain) to 10 (worst possible pain).
Patients should complete the electronic diary at bedtime.
The 11-point Likert scale will also be used for assessment of night pain and worst pain each day, and evaluated as weekly means.
Average interference was calculated as the average of non-missing scores of individual interference items.
|
Baseline, Week 13
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Brief Pain Inventory - Severity (BPI-S) and Interference (BPI-I) Scores
Tidsram: Baseline, Week 13, Week 54
|
BPI-S and BPI-I are self-reported scales measuring severity of pain and interference on function.
Severity scores: 0 (no pain) to 10 (severe pain) on each question assessing worst pain, least pain, and average pain in past 24 hours, and pain right now.
Interference scores: 0 (does not interfere) to 10 (completely interferes) on each question assessing interference of pain in past 24 hours for general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life.
Average interference = average of non-missing scores of individual interference items.
|
Baseline, Week 13, Week 54
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Clinical Global Impression of Severity (CGI-Severity)
Tidsram: Baseline, Week 13, Week 54
|
Measures severity of illness at the time of assessment.
Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).
|
Baseline, Week 13, Week 54
|
|
Number of Participants Who Responded to Treatment at Week 13 Endpoint Based on 30% Score Reduction Criteria
Tidsram: Week 13
|
Response to treatment was defined as at least a 30% reduction of weekly mean score in in Brief Pain Inventory (BPI) Average Pain severity ratings from baseline to endpoint.
The number of participants who met this criteria are presented.
|
Week 13
|
|
Number of Participants Who Responded to Treatment at Week 13 Endpoint Based on 50% Score Reduction Criteria
Tidsram: Week 13
|
Response to treatment was defined as at least a 50% reduction of weekly mean score in in Brief Pain Inventory (BPI) Average Pain severity ratings from baseline to endpoint.
The number of participants who met this criteria are presented.
|
Week 13
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Athens Insomnia Scale
Tidsram: Baseline, Week 13, Week 54
|
Estimates sleep difficulty.
Consists of 8 items rated on a 4-point scale of 0 (no problem at all) to 3 (very serious problem).
Total score of the 8-item version ranges from 0-24.
|
Baseline, Week 13, Week 54
|
|
Change From Baseline to Week 13 Endpoint in 36-Item Short-Form Health Survey (SF-36)
Tidsram: Baseline, Week 13
|
The SF-36 Health Status Survey is a generic, health-related scale assessing subjects' quality of life on 8 domains: physical functioning, social functioning, bodily pain, vitality, mental health, role-physical, role-emotional and general health and 2 summary scores (mental component summary [MCS] and physical component summary [PCS]).
MCS and PCS scores=0-100 (higher scores indicate better health status).
Domain scores: general health=5-25; physical functioning=10-30; role-physical=4-8; role-emotional=3-6; social functioning=2-10; bodily pain=2-11; vitality=4-24; mental health=5-30.
|
Baseline, Week 13
|
|
Change From Baseline to Week 13 Endpoint in EuroQoL Questionnaire - 5 Dimension (EQ-5D)
Tidsram: Baseline, Week 13
|
The EuroQoL Questionnaire - 5 Dimension (EQ-5D) is a generic, multidimensional, health-related, quality-of-life instrument.
The profile allows patients to rate their health state in 5 health domains: mobility, self-care, usual activities, pain/discomfort, and mood.
A single score between 1 and 3 is generated for each domain.
For each patient, the outcome rating on the 5 domains will be mapped to a single index through an algorithm.
The index ranges between 0 and 1, with the higher score indicating a better health state perceived by the patient.
Scores presented used the UK Based Index Score.
|
Baseline, Week 13
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Work Productivity and Activity Impairment Instrument (WPAI) Scores
Tidsram: Baseline, Week 13, Week 54
|
WPAI: self-administered instrument used to measure effect of general health and symptom severity on work productivity and regular activities and yields 4 types of scores: Absenteeism (work time missed); Presenteeism (impairment at work/reduced on-the-job effectiveness); Work Productivity Loss (overall work impairment/absenteeism plus presenteeism); and Activity Impairment. Higher scores are indicative of greater impairment.
|
Baseline, Week 13, Week 54
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Beck Depression Inventory (BDI-II) Total Scores
Tidsram: Baseline, Week 13, Week 54
|
A 21-item, patient-completed questionnaire to assess characteristics of depression.
Each of the 21 items corresponding to a symptom of depression is summed to give a single score.
There is a four-point scale for each item ranging from 0 to 3. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.
|
Baseline, Week 13, Week 54
|
|
Change From Baseline to Week 13 Endpoint in Hospital Anxiety and Depression Scale (HADS) Scores
Tidsram: Baseline, Week 13
|
A 14-item questionnaire with 2 subscales: anxiety and depression.
Each item is rated on a 4-point scale, giving maximum scores of 21 for anxiety and depression.
Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7, 'normal.'
|
Baseline, Week 13
|
|
Laboratory Assessments That Were Statistically Significantly Different Between Treatment Groups in Change From Baseline to Week 13 Endpoint: Bicarbonate
Tidsram: Baseline, Week 13
|
Baseline, Week 13
|
|
|
Laboratory Assessments That Were Statistically Significantly Different Between Treatment Groups in Change From Baseline to Week 13 Endpoint: Uric Acid
Tidsram: Baseline, Week 13
|
Baseline, Week 13
|
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Pulse Rate
Tidsram: Baseline, Week 13, Week 54
|
Baseline, Week 13, Week 54
|
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Blood Pressure
Tidsram: Baseline, Week 13, Week 54
|
Baseline, Week 13, Week 54
|
|
|
Change From Baseline to Week 13 and Week 54 Endpoints in Vital Signs: Weight
Tidsram: Baseline, Week 13, Week 54
|
Baseline, Week 13, Week 54
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Serious Adverse Events During the Dose-Blind Extension Phase
Tidsram: Week 13 though Week 54
|
Serious adverse events during the extension phase reported based on the original treatment group to which the patient was randomized.
Dictionary used was MedDRA 11.0.
|
Week 13 though Week 54
|
|
Treatment-Emergent Adverse Events Occurring in at Least 5 Percent of Patients During the Dose-Blind Extension Phase
Tidsram: Week 13 through Week 54
|
Treatment-emergent adverse events during the extension phase reported based on the original treatment group to which the patient was randomized.
Dictionary used was MedDRA 11.0.
|
Week 13 through Week 54
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- Williamson OD, Schroer M, Ruff DD, Ahl J, Margherita A, Sagman D, Wohlreich MM. Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials. Clin Ther. 2014 Apr 1;36(4):544-51. doi: 10.1016/j.clinthera.2014.02.009. Epub 2014 Mar 17.
- Skljarevski V, Zhang S, Chappell AS, Walker DJ, Murray I, Backonja M. Maintenance of effect of duloxetine in patients with chronic low back pain: a 41-week uncontrolled, dose-blinded study. Pain Med. 2010 May;11(5):648-57. doi: 10.1111/j.1526-4637.2010.00836.x. Epub 2010 Apr 13.
- Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Efficacy and safety of duloxetine in patients with chronic low back pain. Spine (Phila Pa 1976). 2010 Jun 1;35(13):E578-85. doi: 10.1097/BRS.0b013e3181d3cef6.
Användbara länkar
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2007
Primärt slutförande (Faktisk)
1 december 2007
Avslutad studie (Faktisk)
1 oktober 2008
Studieregistreringsdatum
Först inskickad
17 januari 2007
Först inskickad som uppfyllde QC-kriterierna
17 januari 2007
Första postat (Uppskatta)
19 januari 2007
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
20 november 2009
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
18 november 2009
Senast verifierad
1 november 2009
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Ryggont
- Ländryggssmärta
- Läkemedels fysiologiska effekter
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Agenter från det perifera nervsystemet
- Analgetika
- Sensoriska systemagenter
- Psykotropa droger
- Neurotransmittorupptagshämmare
- Membrantransportmodulatorer
- Antidepressiva medel
- Dopaminmedel
- Serotonin- och noradrenalinåterupptagshämmare
- Duloxetinhydroklorid
Andra studie-ID-nummer
- 10544 (Annan identifierare: Fred Hutch/University of Washington Cancer Consortium)
- F1J-MC-HMEN
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Duloxetine
-
Shanghai Mental Health CenterJiangsu Nhwa Pharmaceutical Co., Ltd.Avslutad
-
Boehringer IngelheimAvslutadDiabetiska neuropatier | Depressiv sjukdom, majorTyskland
-
University of MinnesotaHoffmann-La Roche; Minnesota Medical FoundationAvslutad
-
Nearmedic Plus LLCAvslutadHerpes simplex | Herpes Genitalis | Herpes | Herpes oralt | Herpes Simplex 2Ryska Federationen
-
Belfast Health and Social Care TrustQueen's University, Belfast; Northern Ireland Clinical Trials UnitAvslutad
-
ContraVir Pharmaceuticals, Inc.AvslutadBältros | Postherpetisk neuralgi | BältrosFörenta staterna
-
University of PittsburghEli Lilly and Company; National Institutes of Health (NIH)AvslutadRyggont | Major depressiv sjukdom | ÅldrigFörenta staterna
-
Hamilton Health Sciences CorporationSt. Joseph's Healthcare Hamilton; Eli Lilly and Company; McMaster UniversityOkänd
-
New York State Psychiatric InstituteEli Lilly and CompanyAvslutadDysthymic Disorder | Depressiv sjukdom NOSFörenta staterna
-
Peking UniversityHar inte rekryterat ännuMajor depressiv sjukdom | Kronisk visceral smärta